Is Zydus Lifesciences the Best Stock in Its Sector? A Look at the Numbers

Is Zydus Lifesciences the best stock in its sector? The stock trades on the NSE at Rs 1,119 as of 12 October 2026, within its 52-week range of Rs 835.50 to Rs 1,232.10. Zydus Lifesciences Ltd, based in Ahmedabad and formerly known as Cadila Healthcare, is a global pharmaceutical company with generics, branded formulations, APIs, consumer wellness and animal health businesses.

Zydus Lifesciences sits in the Healthcare sector, and its 18.59% ROE and 24.22x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Zydus Lifesciences

Zydus Lifesciences Ltd, based in Ahmedabad and formerly known as Cadila Healthcare, is a global pharmaceutical company with generics, branded formulations, APIs, consumer wellness and animal health businesses. It has a significant presence in the US generics market and has invested in vaccines and speciality and biologics pipelines. The stock trades about 9 percent below its 52-week high and about 34 percent above its 52-week low. At a market capitalisation of Rs 1,11,232 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Zydus Lifesciences the Best Stock in Its Sector?

Zydus Lifesciences makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 18.59% ROE with a 24.22x P/E against the sector's 36.69x Industry P/E. Zydus Lifesciences' 24.22x P/E is well below the 36.69x Industry P/E and is paired with an 18.59% ROE and a 0.46 debt to equity ratio, although its 0.09% dividend yield is small and pharma earnings can swing with US pricing.

Metric	Zydus Lifesciences
CMP (NSE)	Rs 1,119.30
52-Week High / Low	Rs 1,232.10 / Rs 835.50
Market Cap	Rs 1,11,232 Cr
P/E (TTM) vs Industry P/E	24.22x vs 36.69x
P/B	4.10
ROE	18.59%
EPS (TTM)	Rs 46.04
Dividend Yield	0.09%
Debt to Equity	0.46

Compare Zydus Lifesciences Against Other Healthcare Sector Stocks

How Zydus Lifesciences Compares Against Its Healthcare Sector Peers

The table below sets Zydus Lifesciences against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Zydus Lifesciences	1,11,232	24.22	18.59%	0.46
Lupin	89,629	16.15	23.76%	0.29
Alkem Laboratories	62,954	28.56	16.66%	0.15
Peer average (2 companies)	-	22.35	20.21%	0.22

Against this peer set, Zydus Lifesciences's 18.59% ROE is below the 20.21% peer average, and its P/E of 24.22x runs above the peer average of 22.35x. Zydus Lifesciences' 24.22x P/E is well below the 36.69x Industry P/E and is paired with an 18.59% ROE and a 0.46 debt to equity ratio, although its 0.09% dividend yield is small and pharma earnings can swing with US pricing.

What Makes Zydus Lifesciences Worth Watching in Healthcare

• Valuation gap: A 24.22x P/E against a 36.69x Industry P/E is a clear discount to the sector benchmark.
• Return ratios: An 18.59% ROE shows healthy profitability on equity.
• Scale: A market capitalisation of Rs 1,11,232 Cr makes it one of the larger listed pharma companies.

Zydus Lifesciences Valuation: Is It Justified?

Zydus Lifesciences' 24.22x P/E is well below the 36.69x Industry P/E and is paired with an 18.59% ROE and a 0.46 debt to equity ratio, although its 0.09% dividend yield is small and pharma earnings can swing with US pricing. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is VIP Clothing the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Zydus Lifesciences and other Healthcare sector stocks.

How to Track Zydus Lifesciences Before You Invest

Before deciding whether Zydus Lifesciences deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

1. Open the Univest Screener and search for Zydus Lifesciences to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
2. Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Zydus Lifesciences earns a place in the best stock in its sector conversation on the strength of a 18.59% ROE and a P/E of 24.22x against a 36.69x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Zydus Lifesciences the best stock in its sector?

Ans. Zydus Lifesciences has a 18.59% ROE and trades at 24.22x P/E against a 36.69x Industry P/E, and compares below the peer average ROE of 20.21% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Zydus Lifesciences?

Ans. Zydus Lifesciences was trading at Rs 1,119.30 on the NSE as of 12 October 2026, within its 52-week range of Rs 835.50 to Rs 1,232.10.

What sector does Zydus Lifesciences belong to?

Ans. Zydus Lifesciences is classified under the Healthcare sector on Univest.

How does Zydus Lifesciences compare to its sector peers on P/E?

Ans. Zydus Lifesciences's P/E of 24.22x is above the 22.35x average of the 2 named peers compared in this article.

What is Zydus Lifesciences's return on equity?

Ans. Zydus Lifesciences reported a return on equity of 18.59%, which is below the 20.21% average of its named peers in this comparison.

Should I invest in Zydus Lifesciences based on its sector position?

Ans. Zydus Lifesciences's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.

{"@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [{"@type": "Question", "name": "Is Zydus Lifesciences the best stock in its sector?", "acceptedAnswer": {"@type": "Answer", "text": "Zydus Lifesciences has a 18.59% ROE and trades at 24.22x P/E against a 36.69x Industry P/E, and compares below the peer average ROE of 20.21% in this article's named comparison, so the answer depends on what an investor is prioritising."}}, {"@type": "Question", "name": "What is the current share price of Zydus Lifesciences?", "acceptedAnswer": {"@type": "Answer", "text": "Zydus Lifesciences was trading at Rs 1,119.30 on the NSE as of 12 October 2026, within its 52-week range of Rs 835.50 to Rs 1,232.10."}}, {"@type": "Question", "name": "What sector does Zydus Lifesciences belong to?", "acceptedAnswer": {"@type": "Answer", "text": "Zydus Lifesciences is classified under the Healthcare sector on Univest."}}, {"@type": "Question", "name": "How does Zydus Lifesciences compare to its sector peers on P/E?", "acceptedAnswer": {"@type": "Answer", "text": "Zydus Lifesciences's P/E of 24.22x is above the 22.35x average of the 2 named peers compared in this article."}}, {"@type": "Question", "name": "What is Zydus Lifesciences's return on equity?", "acceptedAnswer": {"@type": "Answer", "text": "Zydus Lifesciences reported a return on equity of 18.59%, which is below the 20.21% average of its named peers in this comparison."}}, {"@type": "Question", "name": "Should I invest in Zydus Lifesciences based on its sector position?", "acceptedAnswer": {"@type": "Answer", "text": "Zydus Lifesciences's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor."}}]}